NCT00096018View on ClinicalTrials.gov

Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

November 30, 2010

Study Completion Date

May 31, 2012

Conditions
Leukemia
Interventions
DRUG

fludarabine phosphate

Given IV

DRUG

thalidomide

Orally

Trial Locations (1)

14263-0001

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

Roswell Park Cancer Institute

OTHER

NCT00096018 - Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter